Revolution Medicines
Utility Patent Applications
Last updated:
List of all Revolution Medicines patents 26 in total
| Status | Patent |
|---|---|
Application | Utility: COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF Filling date: 6 Sep 2025 Issue date: 12 May 2022 |
Application | Utility: COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF Filling date: 6 Sep 2025 Issue date: 12 May 2022 |
Application | Utility: BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Filling date: 6 Sep 2025 Issue date: 5 May 2022 |
Application | Utility: RAS INHIBITORS Filling date: 6 Sep 2025 Issue date: 7 Apr 2022 |
Application | Utility: IDENTIFYING NEW THERAPEUTIC AGENTS Filling date: 6 Sep 2025 Issue date: 17 Mar 2022 |
Application | Utility: SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER Filling date: 6 Sep 2025 Issue date: 3 Feb 2022 |
Application | Utility: METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES Filling date: 6 Sep 2025 Issue date: 30 Dec 2021 |
Application | Utility: C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors Filling date: 6 Sep 2025 Issue date: 4 Nov 2021 |
Application | Utility: METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES Filling date: 6 Sep 2025 Issue date: 16 Sep 2021 |
Application | Utility: SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2- -OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR Filling date: 6 Sep 2025 Issue date: 19 Aug 2021 |
Application | Utility: SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER Filling date: 6 Sep 2025 Issue date: 27 May 2021 |
Application | Utility: BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Filling date: 6 Sep 2025 Issue date: 13 May 2021 |
Application | Utility: RAS INHIBITORS Filling date: 6 Sep 2025 Issue date: 6 May 2021 |
Application | Utility: RAS INHIBITORS Filling date: 6 Sep 2025 Issue date: 6 May 2021 |
Application | Utility: RAS INHIBITORS Filling date: 6 Sep 2025 Issue date: 6 May 2021 |
Application | Utility: 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS Filling date: 6 Sep 2025 Issue date: 8 Apr 2021 |
Application | Utility: RAPAMYCIN ANALOGS AS MTOR INHIBITORS Filling date: 6 Sep 2025 Issue date: 1 Apr 2021 |
Application | Utility: POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Filling date: 6 Sep 2025 Issue date: 31 Dec 2020 |
Application | Utility: SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER Filling date: 6 Sep 2025 Issue date: 26 Nov 2020 |
Application | Utility: COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF Filling date: 6 Sep 2025 Issue date: 5 Nov 2020 |
Application | Utility: PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Filling date: 6 Sep 2025 Issue date: 29 Oct 2020 |
Application | Utility: COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF Filling date: 6 Sep 2025 Issue date: 25 Jun 2020 |
Application | Utility: COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF Filling date: 6 Sep 2025 Issue date: 25 Jun 2020 |
Application | Utility: PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Filling date: 6 Sep 2025 Issue date: 16 Jan 2020 |
Application | Utility: BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Filling date: 6 Sep 2025 Issue date: 16 Jan 2020 |
Application | Utility: C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors Filling date: 6 Sep 2025 Issue date: 7 Nov 2019 |
Showing 1 to 26 of 26 patents.